Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease
Stergios A Polyzos, Jannis Kountouras, Efthimia Zafeiriadou, Kalliopi Patsiaoura, Evangelia Katsiki, Georgia Deretzi, Christos Zavos, Georgios Tsarouchas, Pantelitsa Rakitzi, Aristidis Slavakis, Stergios A Polyzos, Jannis Kountouras, Efthimia Zafeiriadou, Kalliopi Patsiaoura, Evangelia Katsiki, Georgia Deretzi, Christos Zavos, Georgios Tsarouchas, Pantelitsa Rakitzi, Aristidis Slavakis
Abstract
Aim: The renin-angiotensin-aldosterone system has been implicated in the pathogenesis of insulin resistance and nonalcoholic fatty liver disease (NAFLD). The beneficial effect of spironolactone in a mouse model with diabetes and NAFLD has recently been reported. The main aim was assessment of the effect of spironolactone on serum metabolic parameters and insulin resistance in patients with NAFLD.
Methods: This study includes preliminary results of a single-centre randomised controlled trial of treatment with vitamin E (group 1, 10 patients) versus spironolactone plus vitamin E (group 2, 10 patients) in biopsy-proven NAFLD. Serum transaminases, lipids, potassium, sodium, glucose and insulin were measured, and homeostatic model assessment-insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated before and 8( )weeks after baseline assessment.
Results: Insulin was decreased within group 2 (15.3 ± 2.7 at baseline vs. 10.3 ± 5.0 at week 8, p = 0.013). Although no difference in glucose was observed, HOMA-IR significantly decreased (4.4 ± 0.9 vs. 2.8 ± 0.5, respectively, p = 0.047). QUICKI was increased, but not statistically significantly.
Conclusions: Spironolactone and vitamin E combined therapy seems to exhibit a favourable effect on serum insulin and HOMA-IR in patients with NAFLD. If validated in a large-scale clinical trial, it may prove an inexpensive therapeutic approach for the management of NAFLD patients.
Trial registration: ClinicalTrials.gov NCT01147523.
Source: PubMed